Selective serotonin reuptake inhibitors

BMJ 2005; 330 doi: http://dx.doi.org/10.1136/bmj.330.7488.420-b (Published 17 February 2005) Cite this as: BMJ 2005;330:420

THREAD trial may show way forward

  1. Robert Peveler, professor of liaison psychiatry ([email protected]),
  2. Tony Kendrick, professor of primary medical care,
  3. THREAD Study Group
  1. University of Southampton, Royal South Hants Hospital, Southampton SO14 0YG
  2. University of Southampton, Aldermoor Health Centre, Southampton SO16 5ST

    EDITOR—Geddes and Cipriani comment that available randomised evidence does not provide reliable estimates of the costs and benefits of treatment with selective serotonin reuptake inhibitors (SSRIs) in patients with varying degrees of severity and laments the decline in non-commercial funding.1 Recent guidelines from the National Institute for National Excellence (NICE) also lack evidence.2 The NHS health technology assessment programme is funding a trial …

    View Full Text

    Sign in

    Log in through your institution

    Free trial

    Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
    Sign up for a free trial